Investor Overview

  • Webcast Image Webcast
    Aimmune Therapeutics Conference Call
    October 16, 2017
    8:30 AM EDT
  • Webcast Image Webcast
    Aimmune Therapeutics at Bank of America Merrill Lynch Global Healthcare Conference
    September 15, 2017
    5:40 AM EDT
  • Webcast Image Webcast
    Aimmune Therapeutics at BioCentury NewsMakers In The BioTech Industry Conference
    September 08, 2017
    11:00 AM EDT

Global - Overview

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational product using CODIT™, AR101 for the treatment of peanut allergy, has... more >

Recent News

more >

Upcoming Events

more >
There are currently no events to display.